Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Clin Infect Dis 2020 Feb 03;70(4):687-691

Date

06/11/2019

Pubmed ID

31179503

Pubmed Central ID

PMC7319267

DOI

10.1093/cid/ciz486

Scopus ID

2-s2.0-85078870542 (requires institutional sign-in at Scopus site)   17 Citations

Abstract

Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15-19 years. Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).

Author List

Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K

Author

Peter Havens MD Emeritus Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Anti-HIV Agents
Bone Density
Emtricitabine
HIV Infections
Homosexuality, Male
Humans
Male
Pre-Exposure Prophylaxis
Sexual and Gender Minorities
Tenofovir
Young Adult